Arris Pharmaceutical Corp. has completed a $5.2 millionprivate placement. The South San Francisco, Calif.-basedcompany will use the proceeds to develop therapeutics foranemia, atherosclerosis and asthma and to continuedevelopment of its core technologies, which combinebiological science, medicinal chemistry and artificialintelligence.

Participants included previous investors C.W. Group; Kleiner,Perkins, Caufield & Byers; Venrock Associates; DSV Partners;and Fairfield Ventures. Accel Partners is a new investor.

Arris has raised $5.8 million in two previous rounds offinancing since May 1989.

(c) 1997 American Health Consultants. All rights reserved.